Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.9
5.2
Journals
Vaccines
Special Issues
Veterinary Vaccine Research at the Frontline of Vaccinology
share announcement

Veterinary Vaccine Research at the Frontline of Vaccinology

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Veterinary Vaccines".

Deadline for manuscript submissions: closed (30 September 2022) | Viewed by 6943

Special Issue Editors

Prof. Gregers Jungersen

E-Mail Website
Guest Editor
Statens Serum Institut, Veterinary Vaccine Research, Infectious Disease Immunology, Center for Vaccine Research, Artillerivej 5, 2300 Copenhagen S, Denmark
Interests: veterinary immunology; vaccines; mucosal immunology; immunological correlates of protection; cell-mediated immunity
Dr. Gitte Erbs

E-Mail Website
Guest Editor
Statens Serum Institut, Veterinary Vaccine Research, Infectious Disease Immunology, Center for Vaccine Research, Artillerivej 5, 2300 Copenhagen S, Denmark
Interests: porcine immunology; vaccine design and delivery; enterotoxigenic E. coli; mucosal immunology; host–pathogen interactions; antigen selection

Special Issue Information

Dear Colleagues,

The COVID-19 pandemic has shown how years of progress in vaccine technologies have been utilized in vaccine development against an emerging infection at a previously unprecedented pace. There are, however, many infectious disease problems still to be solved, and veterinary vaccine research may hold solutions to these that can benefit both human and veterinary vaccine development. Here, we aim to present advances in veterinary vaccine research and development that hold promise to deliver new and exciting opportunities for further improvement of immunity against infectious challenges for humans and animals. Contributions may include how an understanding of immunological correlates of protection guides the design and formulation of vaccines and adjuvants, how mucosal immunity can be obtained through vaccination, advances in design of antigen presentation and delivery, e.g., via mRNA or virus replicon technology, and development of vaccines against parasites. Altogether, this collection will also emphasize how large animals can be used as relevant experimental models for advancing vaccine development for infections where no vaccines currently provide sufficient protection for humans.

Prof. Gregers Jungersen
Dr. Gitte Erbs
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • mucosal vaccines
  • correlates of immunity in vaccine design
  • engineered antigenic expression
  • antiparasitic vaccines
  • large animal experimental models for vaccine development

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 2277 KiB  
Article
Exploring Prime-Boost Vaccination Regimens with Different H1N1 Swine Influenza A Virus Strains and Vaccine Platforms
by Anna Parys, Elien Vandoorn, Koen Chiers, Katharina Passvogel, Walter Fuchs, Thomas C. Mettenleiter and Kristien Van Reeth
Vaccines 2022, 10(11), 1826; https://doi.org/10.3390/vaccines10111826 - 29 Oct 2022
Cited by 3 | Viewed by 1663
Abstract
In a previous vaccination study in pigs, heterologous prime-boost vaccination with whole-inactivated H1N1 virus vaccines (WIV) induced superior antibody responses and protection compared to homologous prime-boost vaccination. However, no pan-H1 antibody response was induced. Therefore, to stimulate both local and systemic immune responses, [...] Read more.
In a previous vaccination study in pigs, heterologous prime-boost vaccination with whole-inactivated H1N1 virus vaccines (WIV) induced superior antibody responses and protection compared to homologous prime-boost vaccination. However, no pan-H1 antibody response was induced. Therefore, to stimulate both local and systemic immune responses, we first vaccinated pigs intranasally with a pseudorabies vector vaccine expressing the pH1N1 hemagglutinin (prvCA09) followed by a homologous or heterologous WIV booster vaccine. Homologous and heterologous WIV–WIV vaccinated groups and mock-vaccinated or prvCA09 single-vaccinated pigs served as control groups. Five weeks after the second vaccination, pigs were challenged with a homologous pH1N1 or one of two heterologous H1N2 swine influenza A virus strains. A single prvCA09 vaccination resulted in complete protection against homologous challenge, and vector–WIV vaccinated groups were significantly better protected against heterologous challenge compared to the challenge control group or WIV–WIV vaccinated groups. Furthermore, vector–WIV vaccination resulted in broader hemagglutination inhibition antibody responses compared to WIV–WIV vaccination and higher numbers of antibody-secreting cells in peripheral blood, draining lymph nodes and nasal mucosa. However, even though vector–WIV vaccination induced stronger antibody responses and protection, we still failed to induce a pan-H1 antibody response. Full article
(This article belongs to the Special Issue Veterinary Vaccine Research at the Frontline of Vaccinology)
►▼ Show Figures

Figure 1

Review

Jump to: Research

24 pages, 1394 KiB  
Review
Progress towards the Elusive Mastitis Vaccines
by Pascal Rainard, Florence B. Gilbert, Rodrigo P. Martins, Pierre Germon and Gilles Foucras
Vaccines 2022, 10(2), 296; https://doi.org/10.3390/vaccines10020296 - 15 Feb 2022
Cited by 15 | Viewed by 4329
Abstract
Mastitis is a major problem in dairy farming. Vaccine prevention of mammary bacterial infections is of particular interest in helping to deal with this issue, all the more so as antibacterial drug inputs in dairy farms must be reduced. Unfortunately, the effectiveness of [...] Read more.
Mastitis is a major problem in dairy farming. Vaccine prevention of mammary bacterial infections is of particular interest in helping to deal with this issue, all the more so as antibacterial drug inputs in dairy farms must be reduced. Unfortunately, the effectiveness of current vaccines is not satisfactory. In this review, we examine the possible reasons for the current shortcomings of mastitis vaccines. Some reasons stem from the peculiarities of the mammary gland immunobiology, others from the pathogens adapted to the mammary gland niche. Infection does not induce sterilizing protection, and recurrence is common. Efficacious vaccines will have to elicit immune mechanisms different from and more effective than those induced by infection. We propose focusing our research on a few points pertaining to either the current immune knowledge or vaccinology approaches to get out of the current deadlock. A possible solution is to focus on the contribution of cell-mediated immunity to udder protection based on the interactions of T cells with the mammary epithelium. On the vaccinology side, studies on the orientation of the immune response by adjuvants, the route of vaccine administration and the delivery systems are among the keys to success. Full article
(This article belongs to the Special Issue Veterinary Vaccine Research at the Frontline of Vaccinology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop